World Health Organization has approved the vaccine for rotavirus which affects children under the age of five. This vaccine is the product of Glaxo Smith Kline. WHO has certified the quality, safety and efficacy of this vaccine called Rotarix for use by Unicef in its vaccination programmes.
Children affected from rotavirus develop severe diarrhea and gastroenteritis. Around 600000 deaths are reported every year due to rotavirus infections. According to Jean Stephenne who is the vaccines head of Glaxo, Africa and Latin America are the countries where Rotarix is registered first.
Rotarix approval by WHO enables the availability of this vaccine in almost ninety nations across the world. Twenty percent of this vaccine market is held by Europe.